{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-031987","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.604519+00:00","generated_at":"2026-05-16T06:05:48.092427+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James","bullets":["Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.","Board approved restructuring plan; expects $2.4M-$2.6M in one-time charges in Q1 2026.","Chief Medical Officer Qasim Ahmad's employment will end effective Feb 15, 2026.","Company implementing significant global workforce reduction to reduce operating expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-031987","json":"https://secwatch.observer/filing/0001193125-26-031987.json","markdown":"https://secwatch.observer/filing/0001193125-26-031987.md","text":"https://secwatch.observer/filing/0001193125-26-031987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/0001193125-26-031987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/d13704d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:05:48.092427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}